NEW YORK, Sept. 28 - Aptus Genomics, a biotech company that focuses on G-protein coupled receptor genes, has appointed Krystyna Belendiuk as president, the company said on Friday. 

"I am very pleased to have someone with Krystyna's knowledge and experience join the Aptus management team," Kevin Chance, founder and CEO of Aptus, said in a statement. 

Before joining Aptus, Belendiuk was co-founder, director, and senior vice president of Pharmavene, now known as Shire Laboratories.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

This year's Breakthrough Prize winners include a pair that developed a therapy for spinal muscular atrophy.

The New York Times reports on how white supremacists misconstrue genetic research, concerning many geneticists.

Researchers find that people's genetics influence their success at university, but that it is not the only factor.

In Nature this week: approach to identify genetic variants that affect trait variability, application of read clouds to microbiome samples, and more.